Lineage Cell Therapeutics Inc (LCTX)

[Cincinnatus]

Brief summary of highlights of AST 11/14/17 CC

1. Spinal meeting with FDA by end of Q1/18
2. RMAT designation may include endpoints leading to early FDA approval.
3. Discussions to take advantage of Japan's possibly quicker approval process. Other interested business development inquiries(multiple parties)??
4. Expansion of ongoing spinal study from C5-C7 patients now to include C4-C7.
5. Possibility to find partners for treating other cancers when results of small lung cancer trial results are reported
6. Reducing monthly cash burn from $2M/month to $1.3M/month in 2018